Product Information
ABACAVIR-LAMIVUDINE 600-300 MG is a generic product labeled by Laurus Labs Limited, priced at $1.4836 per EA under NDC 42385096230. Its NADAC has been published 197 times since Dec 28, 2022.
FDA first approved this application on Jul 25, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600; 300 mg/1; mg/1
Manufacturer
Laurus Labs LimitedNDC
42385096230
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ABACAVIR SULFATE; LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA216332FDA Approved
7/25/2022
TE Code
AB
On Market Since
7/25/2022
Pharmacological Classes
Price Statistics
The NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has been published 197 times since Dec 28, 2022, and over the history we have for it it has declined 42.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4836 per EA |
|---|---|
| All-time high | $2.5767 (Feb 15, 2023) |
| All-time low | $1.2091 (Nov 22, 2023) |
| 52-week high | $1.5668 |
| 52-week low | $1.2621 |
| Median price | $1.5175 |
| Average price | $1.5957 |
| Largest weekly change | -39.9% (Nov 22, 2023) |
| Weeks tracked | 197 |
| Tracking since | Dec 28, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Laurus Labs Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Abacavir and Lamivudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ABACAVIR-LAMIVUDINE 600-300 MG?
The current National Average Drug Acquisition Cost (NADAC) for ABACAVIR-LAMIVUDINE 600-300 MG, manufactured by Laurus Labs Limited, is $1.4836 per EA (NDC 42385096230), effective Sep 30, 2026.
How has the price of ABACAVIR-LAMIVUDINE 600-300 MG changed over time?
Over the history we have for it, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has declined 42.4%. It has been tracked across 197 weekly CMS publications since Dec 28, 2022.
What are the highest and lowest recorded NADAC prices for ABACAVIR-LAMIVUDINE 600-300 MG?
Since Dec 28, 2022, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has ranged from a low of $1.2091 (Nov 22, 2023) to a high of $2.5767 (Feb 15, 2023), with a median of $1.5175 per EA.
Are there cheaper alternatives to ABACAVIR-LAMIVUDINE 600-300 MG?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ABACAVIR-LAMIVUDINE 600-300 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures ABACAVIR-LAMIVUDINE 600-300 MG?
ABACAVIR-LAMIVUDINE 600-300 MG (NDC 42385096230) is labeled by Laurus Labs Limited, and CMS classifies it as a generic product.